Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-023-00711-0, published online 07 September 2023
The following paragraph
Radiotracers that are approved by the Food and Drug Administration (FDA) for use in patients with PCa include carbon 11 (11C)-choline, fluorine 18 (18F)-sodium fluoride, 18F-fluciclovine (Axumin®, Blue Earth Diagnostics, Inc., Oxford, UK), gallium 68 (68Ga)-PSMA-11 (institutional use only in US), and 2-(3-{1-carboxy-5-[(6-18F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL; PYLARIFY®, Progenics Pharmaceuticals, Inc. North Billerica, MA; US only).
should read:
Radiotracers that are approved by the Food and Drug Administration (FDA) for use in patients with PCa include carbon 11 (11C)-choline, fluorine 18 (18F)-sodium fluoride, 18F-fluciclovine (Axumin®, Blue Earth Diagnostics, Inc., Oxford, UK), gallium 68 (68Ga)-PSMA-11, and 2-(3-{1-carboxy-5-[(6-18F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL; PYLARIFY®, Progenics Pharmaceuticals, Inc. North Billerica, MA). Access to radiotracers will continue to evolve, therefore, it is recommended to check regulatory authorities in specific countries for current approvals.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Moul, J.W., Shore, N.D., Pienta, K.J. et al. Correction: Application of next-generation imaging in biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis 27, 358 (2024). https://doi.org/10.1038/s41391-024-00791-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-024-00791-6
